.png)
On last week's episode of The Genetics Podcast, host Patrick Short was joined by Dr. Mike Snyder, Director of the Center for Genomics and Personalized Medicine at Stanford University. Known for his work in multiomics and personalized health monitoring, Dr. Snyder shares his career journey and discusses his unique approach of using himself as the first participant in his own studies. Their conversation covers everything from the future of healthcare to the potential of wearables and multiomics data in predicting illness before symptoms show.
Precision medicine is paving the way for better healthcare by providing hope for more personalized and effective treatments for patients. But how is this approach evolving around the world? Our latest report, Mapping the precision medicine landscape: Regional insights and future horizons, takes a deep dive into how precision medicine is shaping healthcare systems across North America, Asia Pacific, Europe, Africa, and Latin America.
Precision medicine is reshaping healthcare by moving away from a one-size-fits-all approach to more personalized care. By understanding each patient's genetic makeup, environment, and lifestyle, healthcare professionals can develop targeted treatment and prevention strategies. In this blog, we’ll explore how this approach is making treatments more effective, identifying at-risk individuals, and potentially reducing healthcare costs while addressing key challenges along the way.
In the latest episode of The Genetics Podcast, host Patrick Short welcomes Dr. Lon Cardon, CEO of the Jackson Laboratory, to discuss his career journey, the rise of genome-wide association studies (GWAS), the shift from candidate gene studies, and the future of drug discovery in both rare and common diseases. With a career spanning academia, industry, and now leading one of the most iconic genetics research institutions, Lon shares his insights into how the field of genetics has evolved and what lies ahead.
While precision medicine holds great promise for both patients and the growth of global markets, there are significant obstacles to be overcome to enable its widespread adoption in a context which ensures equality of access. In this blog, we’ll explore how mind-bending volumes of data, a lack of trained specialists, and the huge costs of drug development all pose challenges which must be addressed to ensure successful implementation of precision medicine strategies internationally.
As the global population ages, understanding the genetic, biological, social, and environmental factors influencing longevity has become a key area of research. Advances in genetics are helping researchers unravel how our genes interact with lifestyle and environmental factors to influence not only how long we live but also how healthily we age. Here, we examine genetic research areas that could shape the future of aging and longevity.
In the latest episode of The Genetics Podcast, host Patrick Short welcomes Nadav Ahituv, Director of the Institute for Human Genetics at the University of California San Francisco (UCSF). Together, they discuss the complex world of gene regulation, covering everything from non-coding DNA to advances in genetic technologies. Nadav shares his research on how gene regulatory elements influence human evolution, disease, and diversity, as well as the cutting-edge methods his lab is using to explore these elements.
Breakthrough technologies and data innovation are driving cost reductions and increasing return on investment in precision medicine, fueling accelerated international market growth. With the sector poised for rapid expansion—the market is projected to reach $50.2 billion by 2028—innovators must adopt a global mindset to tackle the challenges of managing and processing data at an unprecedented scale. Addressing the shortage of trained specialists and confronting emerging ethical challenges will also be critical to unlocking the full potential of the precision medicine market and delivering for patients.
In this episode of The Genetics Podcast, host Patrick Short sits down with Marco Quarta, Co-founder and CEO of Rubedo Life Sciences, to discuss the biology of aging and the innovative work his company is doing to address age-related diseases. They discuss cellular senescence (a biological process where cells stop dividing but remain alive), the challenges of understanding aging at the molecular level, and Rubedo’s unique approach to developing therapeutics targeting aging cells.
Longevity – length of life – is influenced by a complex interplay of genetic, environmental, and epigenetic factors. As the global population ages, understanding the determinants of longevity has become a central focus in the fields of genetics and precision medicine. We’ve recently been having some very interesting discussions around aging on The Genetics Podcast – so here, we explore the key genetic and epigenetic factors that contribute to human lifespan and highlight their potential impact on health outcomes as we age.